Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Vertex Pharmaceuticals
(NQ:
VRTX
)
459.62
+2.59 (+0.57%)
Streaming Delayed Price
Updated: 1:00 PM EDT, Jul 3, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vertex Pharmaceuticals
< Previous
1
2
...
15
16
17
18
19
20
21
22
23
...
62
63
Next >
3 Biopharma Stocks You Don't Want to Miss in the New Bull Market
March 05, 2024
All three have exciting programs on the way.
Via
The Motley Fool
Game Changers: 3 Biotech Stocks That Could Be Multibaggers in the Making
March 05, 2024
These three companies represent the world of biotech stocks and offer a unique blend of high risk and potentially high reward.
Via
InvestorPlace
Biotechs on the Rise: 3 Stocks to Buy for a Shot of Profits
March 04, 2024
Given recent industry performance, the enthusiasm investors have for biotech stocks to buy is low. But these three companies seem promising.
Via
InvestorPlace
ChatGPT Stock Predictions: 3 Biotech Companies the AI Bot Thinks Have 10X Potential
March 04, 2024
Here are three ChatGPT stock predictions for the most unpredictable of biotech stocks that might just have 10x potential.
Via
InvestorPlace
Topics
Artificial Intelligence
Why Editas Medicine Stock Soared as Much as 42% Higher This Week
March 02, 2024
The clinical-stage genome editing company dropped a couple of important announcements for shareholders.
Via
The Motley Fool
$100 Invested In This Stock 15 Years Ago Would Be Worth $1,500 Today
February 27, 2024
Via
Benzinga
What Analysts Are Saying About Vertex Pharmaceuticals Stock
February 20, 2024
Via
Benzinga
3 Magnificent Growth Stocks to Buy in March
March 02, 2024
These three stocks have two important common denominators: the same industry and tremendous growth prospects.
Via
The Motley Fool
Apple Sinks After Wall Street Titan Pulls Magnificent 7 Stock From Conviction List
March 01, 2024
Goldman Sachs is removing Apple from its Conviction List of buy-rated stocks. Looking at the potential reasons why and who replaced the tech giant.
Via
Benzinga
These 4 Stocks Are the "Magnificent Seven" of Healthcare
March 01, 2024
Their growth trajectories aren't as meteoric, but they're still notable.
Via
The Motley Fool
Could These 3 Companies Headline a "Magnificent Seven" of Biotech Stocks?
February 29, 2024
These stocks meet many of the criteria long-term investors look for.
Via
The Motley Fool
Beam Rockets 27%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing Drug
February 27, 2024
Both companies are working on treatments for genetic disorders.
Via
Investor's Business Daily
3 Biotech Stocks Bound to Blast Off By 2029
February 27, 2024
Biotech stocks are risky, but rewarding. These three biotechs specifically could see exponential gains in the coming years.
Via
InvestorPlace
bluebird bio: How to play LEAPS options for growth and income
February 27, 2024
Gene-editing is making huge headlines in the medical sector stemming from the first FDA approval for a CRISPR/cas9 treatment for sickle cell disease SCD and TDT
Via
MarketBeat
Vertex Pharmaceuticals (VRTX) Should Remain Supported
February 27, 2024
Vertex Pharmaceuticals Incorporated (VRTX), is a biotechnology company. It engages in developing & commercializing therapies for treating cystic fibrosis (CF).
Via
Talk Markets
3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow
February 27, 2024
Vertex shares have climbed almost 50% over the past year.
Via
The Motley Fool
Median Drug Prices For Rare Diseases Hit $300K In 2023, Report Highlights Lack of Clear Rationale Behind Escalating Drug Prices
February 26, 2024
Latest pharmaceutical trends in the U.S. as drug prices surged 35% in 2023. Uncover insights into the industry's focus on rare diseases, escalating costs, and the impact on FDA-approved drugs.
Via
Benzinga
Is CRISPR Therapeutics the NVIDIA of gene editing?
February 26, 2024
CRISPR Therapeutics AG (NASDAQ: CRSP) made worldwide headlines when it and partner Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) received the first-ever FDA approv
Via
MarketBeat
Topics
Artificial Intelligence
The Ultimate Growth Stock to Buy With $1,000 Right Now
February 26, 2024
The positives are many and the negatives are few with this high-flying stock.
Via
The Motley Fool
2 Stocks That Could Crush the Market in 2024
February 25, 2024
These companies aren't slowing down, and their addressable markets are widening.
Via
The Motley Fool
Three S&P 500 Giants Lead This List Of Stocks Near Buy Points
February 24, 2024
Watch these five stocks, but the market is slightly extended.
Via
Investor's Business Daily
Topics
Stocks
Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On.
February 23, 2024
Weight-loss drugs from Novo Nordisk and Eli Lilly lead to massive weight loss. But not all of that weight loss is healthy.
Via
Investor's Business Daily
The Best Stocks to Invest $5,000 in Right Now
February 23, 2024
These stocks could be huge winners for long-term investors.
Via
The Motley Fool
3 Biotech Stocks to Turn $10,000 Into $1 Million: February 2024
February 22, 2024
With new innovation and high demand, biotech stocks could offer some of the most explosive opportunities of the year.
Via
InvestorPlace
3 Secret Stocks to Double Your Money by 2028
February 22, 2024
Vertex Pharmaceuticals (VRTX), UiPath (PATH), and Science Applications International (SAIC) are 3 secret stocks to double your money by 2028.
Via
InvestorPlace
Vertex to Participate in Upcoming Investor Conferences
February 20, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Pharmaceuticals Is About to Extend Its Leadership in This Billion-Dollar Market
February 20, 2024
Vertex's main business may be heading for a new era of growth...
Via
The Motley Fool
Cathie Wood Is Betting on This Top Technology: 2 Stocks She Just Bought
February 20, 2024
These exciting players could deliver explosive growth over time.
Via
The Motley Fool
3 Revolutionary Biotech Stocks Poised for 10X Surge
February 19, 2024
Discover three biotech stocks set to soar in a $3.08 trillion market, merging medical innovations with financial growth opportunities.
Via
InvestorPlace
3 Magnificent Growth Stocks to Buy Right Now
February 19, 2024
These stocks share at least two common denominators: a biopharmaceutical focus and great long-term prospects.
Via
The Motley Fool
< Previous
1
2
...
15
16
17
18
19
20
21
22
23
...
62
63
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.